Diabetic ketoacidosis after treatment with pembrolizumab
Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with Pembrolizumab. Key Words Immune Checkpoint inhibit...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-09-01
|
| Series: | Journal of Clinical and Translational Endocrinology Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214624516300193 |